Altre lingue Taysha Gene Therapies, Inc.

Azioni

TSHA

US8776191061

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 02/07/2024			Variaz. 5gg	Var. 1 gen.
2,16 ^USD	-4,42%		-18,80%	+22,03%

01/07	L'insider di Taysha Gene Therapies ha acquistato azioni per un valore di 2.999.999 dollari, secondo un recente deposito SEC	MT
26/06	Taysha Gene Therapies prezza un'offerta di azioni da 75 milioni di dollari, con warrant prefinanziati; le azioni calano	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Taysha Gene Therapies Insider Bought Shares Worth $2,999,999, According to a Recent SEC Filing	01/07
Taysha Gene Therapies Prices $75 Million Offering of Shares, Pre-Funded Warrants; Shares Fall	26/06
Sector Update: Health Care Stocks Mixed Pre-Bell Wednesday	26/06
Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants	26/06
Top Premarket Decliners	26/06
Taysha Gene Therapies Starts $75 Million Common Stock Offering	26/06
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants	26/06
TSHA 102 in clinical evaluation for Rett syndrome: Cohort one data from the REVEAL Phase 1/2 Adolescent Adult and Pediatric trials	18/06
Taysha Gene Therapies Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2 Trials Evaluating TSHA-102 in Rett Syndrome	18/06
Taysha Gene Therapies, Inc. Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2 Trials Evaluating TSHA-102 in Rett Syndrome	18/06
Taysha Gene Therapies to Present Clinical Data from Both REVEAL Phase 1/2 Trials During Company-Hosted Webcast and at 2024 IRSF Rett Syndrome Scientific Meeting	12/06
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	07/06
Taysha Gene Therapies Q1 Net Loss Narrows, Revenue Declines -- Shares Down After Hours	14/05
Taysha Gene Therapies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05
Earnings Flash (TSHA) TAYSHA GENE THERAPIES Reports Q1 Revenue $3.4M, vs. Street Est of $2.6M	14/05
Taysha Gene Therapies Reports First Quarter 2024 Financial Results and Provides Corporate Update	14/05
Taysha Gene Therapies to Release First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 14	07/05
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	03/05
Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome	02/05
Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome	02/05

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Taysha Gene Therapies, Inc.

Azioni

TSHA

US8776191061

Altre lingue

Filtri